Able C&C Co., Ltd. Stock: price and insider trades · South Korea
에이블씨엔씨
No insider purchase over the last 90 days. The latest, by 김명철, was filed 05 Mar 2026.
Who traded when
BuySaleSince the insiders bought
- -7.8%Entry ₩10,450 · Close 30 Oct 2026 ₩9,640
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- ●Executives0DART
- ●Executives0DART
- 3,000 sharesShareKRXDART:20260305000696Canonical exit: 30 May 2026 (T+90)
- ●Executives0DART
- 450,452 sharesKRXDART:20250312000966
- ●Executives0DART
- 450,452 sharesKRXDART:20231110000681
- 450,452 sharesKRXDART:20231106000316
- ShareKRXDART:20230922000484Canonical exit: 30 Oct 2023 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- 450,452 sharesKRXDART:20221007000453
- ●Executives0DART
- ●Executives0DART
17 of 17 declarations
About Able C&C Co., Ltd.
The record at 에이블씨엔씨 (Able C&C Co., Ltd.) fits in 16 filings from 3 filers, published from February 22, 2021 to July 3, 2026. 리프앤바인, classed 대량보유자, files 7, including 4 sales and no purchase. The company itself files 7, with no trade. The only buyer is 김명철 (이사), with 2 purchases. No amount is stated.
Sales therefore prevail, 4 against 2 purchases, or 33% purchases among open-market trades. The calendar is irregular: 1 filing in 2021, 4 in 2022, 5 in 2023, 1 in 2024, 2 in 2025 and 3 in 2026, for trades dated from August 1, 2023 to March 1, 2026. Ten filings are neither purchases nor sales.
Read moreShow less
Capitalisation of KRW 283.5 billion, 64.6% of the capital in insider hands, South Korean company. The latest year holds 3 filings, one of them a purchase. On the 6 filings where the delay is known, a typical filing is published 7 days after the trade.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
